← Back
$ROIV All transactions

Roivant Sciences Ltd.

J

$ Value

$0

Shares

6,205,368

Price

$0

Filed

Jun 27

Insider

Name

Gold Daniel Allen

Title

CIK

0001832142

Roles

Director

Transaction Details

Transaction Date

2025-06-25

Code

J

Table

Non-Derivative

Ownership

Indirect

Equity Swap

No

Shares After

8,441,428

Footnotes

On June 25, 2025, each of QVT Roiv Hldgs Onshore Ltd. and QVT Roiv Hldgs Offshore Ltd. (together, "QVT Roiv"), Fourth Avenue Capital Partners LP ("Fourth Avenue"), QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT Financial Investment Cayman Ltd. ("QVT FIC") made an in-kind distribution on a pro rata basis, for no consideration. One of the investors in QVT Roiv Hldgs Offshore Ltd. contributed its pro rata portion distribution to QVT FIC in order to facilitate the winding down of QVT Roiv Hldgs Offshore Ltd. QVT FIC has no pecuniary interest in such shares. | The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. | QVT Financial LP, a Delaware limited partnership, is the investment manager of QVT Roiv, and shares voting and investment control over the Shares held directly by QVT Roiv. QVT Financial GP LLC ("QVT Financial GP"), a Delaware limited liability company, is the general partner of QVT Financial LP. The reporting person is a Managing Member of QVT Financial GP, sharing voting and investment control over the Common Shares held directly by QVT Roiv and may be deemed to beneficially own such Common Shares. | Management of Fourth Avenue is vested in its general partner, Fourth Avenue Capital Partners GP LLC, a Delaware limited liability company ("Fourth Avenue GP"), which may be deemed to beneficially own the Common Shares held directly by Fourth Avenue. Daniel Gold is a Managing Member of Fourth Avenue GP, sharing voting and investment control over the Common Shares held directly by Fourth Avenue and may be deemed to beneficially own such Common Shares. | The reporting person is one of two directors of QVT P&E Roiv Hldgs Ltd. ("QVT P&E") and QVT Deferred Compensation Holdings Ltd ("QVT DCH"), sharing voting and investment control over the Common Shares held directly by QVT P&E and QVT DCH. | The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. ("QVT FIC"), sharing voting and investment control over the Common Shares held directly by QVT FIC. | Includes shares reporting person received as part of the distribution described in (1) above which is exempted under Rule 16a-9 and/or Rule 16a-13 as a change in form of beneficial ownership and (i) an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy (the "Equity Plan"), which vested on September 12, 2024 and (ii) an annual award of restricted stock units with respect to RSU granted pursuant to the Equity Plan, which is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. | The reporting person is a trustee of trusts and estate planning vehicles, each of which were formed by the reporting person and/or his immediate family members and shares voting and investment control over the Common Shares held directly by these trusts and may be deemed to beneficially own such Common Shares.

Filing Info

Accession No.

0000950170-25-090997

Form Type

4

Issuer CIK

0001635088

Gold Daniel Allen's History

Date Ticker Type Value
2025-06-25 ROIV J $0
2025-06-25 ROIV J $0
2025-06-25 ROIV J $0
2025-06-25 ROIV J $0
2025-06-25 ROIV J $0
2025-06-25 ROIV J $0

Other Insiders at ROIV (90d)

Insider Bought Sold Last
MOMTAZEE JAMES C 2026-04-17
Fitzgerald Meghan $1.9M 2026-03-26
Oren Ilan 2026-04-17
Torti Frank
President and Vant Chair
2026-03-31
Sukhatme Mayukh
President & CIO
2026-03-31
Gline Matthew
CEO
$8.4M 2026-04-16
Venker Eric
President & Immunovant CEO
$5.9M 2026-04-20
Epperly Melissa B, 2026-04-17
Pulik Richard
CFO
2026-04-20
Humes Jennifer
Chief Accounting Officer
$384K 2026-04-20